BUSINESS
Moderna Stock Drops 25% After Cancer Vaccine Data Leak, Results Still Promising
Moderna shares plunged 25% following a data leak about its cancer vaccine, even as trial results showed significant promise for melanoma patients.
Moderna shares plunged 25% following a data leak about its cancer vaccine, even as trial results showed significant promise for melanoma patients.